August 17, 2011
A US-based HIV vaccine trial is expanding the number of participants it will enroll as well as the scientific questions it will probe.
Conducted in 12 US cities, the HIV Vaccine Trials Network 505 (HVTN 505) study will assess a dual vaccine candidate for safety and whether it can prevent infection, not just curb the virus in a person already infected. Enrollment is increasing from about 1,300 men who have sex with men, and transgender women who have sex with men, to 2,200.
The trial's scientific scope changed in response to the RV-144 trial in Thailand in 2009, which proved it was possible to for a vaccine to prevent HIV infection. Though the vaccine's efficacy was too low, the research offered the first-ever evidence that an HIV/AIDS vaccine candidate conferred even modest protection against infection.
The HVTN 505 trial will assess whether the vaccine candidate stimulates both an antibody response to prevent HIV infection and a cell-mediated immune response to mitigate infection, said Warren.
"It uses a prime-boost combination of two different vaccines," Warren said. "One is a DNA vaccine that has snippets of HIV that can't cause HIV at all, but is meant to kind of prime the immune system. And then it has an Adeno 5 (adenovirus type 5, a common cold virus) vaccine boost."
For more information about the trial, sponsored and funded by the National Institute of Allergy and Infectious Diseases, visit: www.hvtn.org/media/news.html. Volunteers should visit: www.hopetakesaction.org/volunteering/index.html.
Voice of America News
08.11.2011; Joe DeCapua
No comments have been made.